Browse Studies — Arctuva

Phase 2

Sacituzumab Tirumotecan to Treat Patients With Brain Metastases From Triple-negative Breast Cancer

This is a multi-site prospective single-arm open-label phase 2 clinical trial including 20 participants with metastatic TNBC and active brain metastases to be …

Metastatic Triple Negative Breast Cancers

Estimated

~$10 – $6,250

Yale UniversityNCT07458113

ENCORE: Multicenter ProspectivE Registry of Sequential ANtibody Drug COnjugates (ADCs) in HER2 Negative Metastatic BREast Cancer (MBC)

Antibody-drug conjugates (ADCs) have demonstrated substantial improvement in progression free survival (PFS) and overall survival (OS) in phase III clinical tr…

HER2-negative Breast CancerHER2 Negative Breast CarcinomaMetastatic Breast Cancer+3 more

Estimated

~$10 – $675

University of California, San FranciscoNCT06774027

Phase 2

Adjuvant Tirzepatide Plus Standard of Care Endocrine Therapy in Patients With Obesity or Overweight Who Have Hormone Receptor-positive, HER2-negative, Node-positive Early Breast Cancer, With Molecular Residual Disease (MRD), as Determined by Circulating Tumor DNA (ctDNA)

This trial aims to asses if tirzepatide-induced weight loss will lead to metabolic and hormonal changes in hormone receptor-positive (HR+), human epidermal gro…

Breast CancerBreast NeoplasmsBreast Cancers

Estimated

~$10 – $7,500

Baylor Research InstituteNCT06517212